Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 467

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

The BOADICEA model of genetic susceptibility to breast and ovarian cancer

Open access
Antoniou, A C, Pharoah, P P D, Smith, P, Easton, D F·2004·British Journal of Cancer
DOI 10.1038/sj.bjc.6602175
Open this paper in CoChat — free account

Abstract

Several genes conferring susceptibility to breast and ovarian cancer, notably BRCA1 and BRCA2, have been identified. The majority of the familial aggregation of breast cancer is, however, not explained by these genes. We have previously derived, using segregation analysis, a susceptibility model (BOADICEA, Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) in which susceptibility to these genes is explained by mutations in BRCA1 and BRCA2 together with a polygenic component reflecting the joint multiplicative effect of multiple genes of small effect on breast cancer risk. Here, we consider the predictions made by this model. The overall familial risks of breast cancer predicted by this model are close to those observed in epidemiological studies. The predicted prevalences of BRCA1 and BRCA2 mutations among unselected cases of breast and ovarian cancer are also consistent with observations from population-based studies. These predictions are closer to the observed values than those obtained using the Claus model and BRCAPRO. The predicted mutation probabilities and cancer risks in individuals with a family history (FH) can differ markedly from those predicted by other models. We conclude that this model provides a rational basis for risk assessment in individuals with a FH of breast or ovarian cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6602175

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 36

  1. Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40: 807–814 · DOI · Paper page
  2. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21: 1–18 · DOI · Paper page
  3. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, Ponder BJ, Easton DF (2002) A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 86: 76–83 · DOI · Paper page
  4. Apicella C, Andrews L, Hodgson SV, Fisher SA, Lewis CM, Solomon E, Tucker K, Friedlander M, Bankier A, Southey MC, Venter DJ, Hopper JL (2003) Log odds of carrying an ancestral mutation in BRCA1 or BRCA2 for a defined personal and family history in an Ashkenazi Jewish woman (LAMBDA). Breast Cancer Res 5: R206–R216 · doi:10.1186/bcr644
  5. Berry DA, Iversen Jr ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20: 2701–2712 · DOI · Paper page
  6. Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349: 1505–1510 · DOI · Paper page
  7. Brown J, Buvkley D, Coulthard A, Dixon AK, Dixon JM, Easton DF, Eeles RA, Evans DG, Gilbert FG, Graves M, Hayes C, Jenkins JP, Jones AP, Keevil SF, Leach MO, Liney GP, Moss SM, Padhani AR, Parker GJ, Pointon LJ, Ponder BA, Redpath TW, Sloane JP, Turnbull LW, Walker LG, Warren RM (2000) Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. Magn Reson Imaging 18: 765–776 · doi:10.1016/s0730-725x(00)00167-3
  8. Claus EB, Risch N, Thompson WD (1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48: 232–242
  9. Claus EB, Risch N, Thompson WD (1994) Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73: 643–651 · DOI · Paper page
  10. Collaborative Group in Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101,986 women without the disease. Lancet 358: 1389–1399 · DOI · Paper page
  11. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 336: 1409–1415 · DOI · Paper page
  12. Davis JG (1997) Predictive genetic tests: problems and pitfalls. Ann NY Acad Sci. 833: 42–46 · DOI
  13. Easton DF (1999) How many more breast cancer predisposition genes are there? Breast Cancer Res 1: 14–17 · DOI · Paper page
  14. Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41: 474–480 · DOI · Paper page
  15. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Canhg-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676–689 · DOI · Paper page
  16. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, Easton DF, Venter DJ (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 8: 741–747
  17. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286: 2251–2256 · DOI · Paper page
  18. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, Venter D, Freeman A, Antoniou A, McGuffog L, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Futreal PA, Peto J, Stoppa-Lyonnet D, Bignon YJ, Stratton MR (2000) The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 6: 782–789
  19. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JCM, Devilee P, Cornelisse CJ, Lasset C, Lenoir G, Barkadottir RB, Egilson V, Hamann U, Chang-Claude J, Sobol H, Weber B, Stratton MR, Easton DF (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90: 1138–1145 · DOI · Paper page
  20. Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20: 2310–2318 · DOI · Paper page
  21. Lange K, Weeks D, Boehnke M (1988) Programs for pedigree analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol 5: 471–472 · DOI · Paper page
  22. Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA (1996) BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 334: 137–142 · DOI · Paper page
  23. Leach MO, Eeles RA, Turnbull LW, Dixon AK, Brown J, Hoff RJ, Coulthard A, Dixon JM, Easton DF, Evans DG, Gilbert FJ, Hawnaur J, Hayes C, Kessar P, Lakhani S, Liney G, Moss SM, Padhani AP, Pointon LJ, Sydenham M, Walker LG, Warren RM, Haites NE, Morrison P, Cole T, Rayter Z, Donaldson A, Shere M, Rankin J, Goudie D, Steel CM, Davidson R, Chu C, Ellis I, Mackay J, Hodgson SV, Homfray T, Douglas F, Quarrell OW, Eccles DM, Gilbert FG, Crothers G, Walker CP, Jones A, Slack N, Britton P, Sheppard DG, Walsh J, Whitehouse G, Teh W, Rankin S, Boggis C, Potterton J, McLean L, Gordon PA, Rubin C (2002) The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). J Exp Clin Cancer Res 21: 107–114
  24. Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, Ostrander EA (2000) Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88: 1393–1402 · doi:10.1002/(sici)1097-0142(20000315)88:6<1393::aid-cncr17>3.0.co;2-p
  25. Marroni F, Aretini P, D'Andrea E, Caligo MA, Cortesi L, Viel A, Ricevuto E, Montagna M, Cipollini G, Ferrari S, Santarosa M, Bisegna R, Bailey-Wilson JE, Bevilacqua G, Parmigiani G, Presciuttini S (2004) Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet 2004: 41:278–41:285
  26. Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62: 145–158 · DOI · Paper page
  27. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91: 943–949 · DOI · Paper page
  28. Peto J, Mack TM (2000) High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 26: 411–414 · DOI · Paper page
  29. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68: 700–710 · DOI · Paper page
  30. Risch N (1990) Linkage strategies for genetically complex traits. I. Multilocus models. Am J Hum Genet 46: 222–228
  31. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, Weber B, Castilla L, Erdos M (1995) A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA 273: 535–541 · DOI · Paper page
  32. Swift M, Chase CL, Morrell D (1990) Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet 46: 21–27 · DOI
  33. The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310–1316 · DOI · Paper page
  34. Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94: 1358–1365 · DOI · Paper page
  35. Thompson WD, Schildkraut JM (1991) Family history of gynaecological cancers: relationships to the incidence of breast cancer prior to age 55. Int J Epidemiol 20: 595–602 · doi:10.1093/ije/20.3.595
  36. Vaittinen P, Hemminki K (2000) Risk factors and age–incidence relationships for contralateral breast cancer. Int J Cancer 88: 998–1002 · doi:10.1002/1097-0215(20001215)88:6<998::aid-ijc25>3.0.co;2-0

Cited by

See all 467

Metadata

Authors
Antoniou, A. C., Pharoah, P. P. D., Smith, P., & Easton, D. F.
Venue
British Journal of Cancer
Publisher
Springer Science and Business Media LLC
Published
2004-09-21
Volume
91
Issue
8
Pages
1580-1590
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
DOI
10.1038/sj.bjc.6602175
OpenAlex
W2012506200
Cited by
467
References
6
FWCI
8.08
Type
journal article
Language
en
Open access
hybrid
Licence
www.springer.com/tdm (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The BOADICEA model of genetic susceptibility to breast and ovarian cancer. https://app.cochat.ai/papers/10.1038/sj.bjc.6602175
The paper
Antoniou, A. C., Pharoah, P. P. D., Smith, P., & Easton, D. F. (2004). The BOADICEA model of genetic susceptibility to breast and ovarian cancer. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6602175

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.